Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3019654 | Revista Española de Cardiología Suplementos | 2008 | 10 Pages |
Abstract
This article reviews the therapeutic benefits of using a combination of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with cardiovascular disease. Clinical trials of what has been termed dual blockade in patients with heart failure have demonstrated small but significant reductions in cardiovascular rehospitalization and mortality. Given after myocardial infarction in patients with heart failure or left ventricular dysfunction, combination treatment was as effective as treatment with either type of agent alone, though there was an increase in the incidence of side effects. However, in clinical practice, the general recommendation that aldosterone antagonists should be administered in cases of advanced heart failure places a limit on the use of dual blockade since triple therapy is contraindicated because of the risk of inducing life-threatening hyperkalemia.
Keywords
SRAABNPARA-IIIECAangiotensin antagonistantagonistas de los receptores de la angiotensina IIangiotensinAngiotensinaangiotensin-converting enzyme inhibitorsInfarto agudo de miocardioReninReninaAcute myocardial infarctionSistema renina-angiotensina-aldosteronaPresión arterialIAMInhibidores de la enzima de conversión de angiotensinaInsuficiencia cardiacaheart failurepéptido natriurético cerebralfracción de eyección
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Enrique Galve, Eduardo Bosch, David GarcÃa-Dorado,